Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations.
Discovery of genetic polymorphism in drug metabolism has contributed a great deal to understanding the variability in dose-concentration relationships introduced by genetic factors, thereby elucidating the mechanisms responsible for unexpected drug reactions. This knowledge should find its way into clinical practice in order to make therapy more efficient and safe. Moreover, genetic factors in drug metabolism should be taken into account during drug development. Therefore, in vitro methods for identifying the metabolic pattern of new compounds during early stages of drug development should be improved. This review summarizes in vitro methods available to identify genetic polymorphism in drug oxidation, in particular the CYP2D6-related polymorphism.
Engel
G
G
Dr. Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Auerbachstrasse, Stuttgart, Germany.
Hofmann
U
U
Kroemer
H K
HK
D000818:Animals; D001711:Biotransformation; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D051381:Rats; D013034:Sparteine / Q000493:pharmacokinetics*
D013034:Sparteine; D019389:Cytochrome P-450 CYP2D6